Currently Enrolling Trials
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer’s Disease. To learn more click here.
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD). To learn more, click here.
This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early intervention on the disease or its symptoms. Length of treatment is dependent on standard of care treatment provided and all study information will be collected during routine standard of care visits. To learn more, click here.
The purpose of the CIN-102-121 study is to test how the study drug, CIN-102, may work in people with idiopathic or diabetic gastroparesis. Gastroparesis, also known as delayed gastric emptying, is a condition that affect the normal movement of the stomach muscles. Normaly, the stomach empties soon after eating a meal. With gastroparesis, it takes food much longer to empty from the stomach. Delayed emptying results in poor breakdown of food and uncomfortable symptoms. To learn more, click here.
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab (Repatha) on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. To learn more, click here.
Consider joining the TRAVERSE research study for men age 45-80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.
If you volunteer and qualify, your participation will last up to approximately 5 years. To learn more visit our contact us page or click here.
Randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor & licogliflozin combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. To learn more, click here.
Osteoporosis is a bone disease in which the body can’t create new bone fast enough to keep up with loss of old bone. This results in bones that are weak and brittle, causing them to break easily. Osteoporosis is most likely to result in a break in the spine, hip or wrist, but other areas can be affected too. This clinical research study is evaluating an investigational patch medication in post menopausal women with osteoporosis. The study doctors want to compare the effectiveness of the patch verion to the approved injectable version of the drug.
If you take part in this study, you’ll be assigned to 1 or 2 study groups. One of these groups will receive the investgational patch medication, while the other will receive the approved injectable medication. You will receive study drug for up to 12 months at no cost. The study drug will either be a patch that you wear on your thigh for 5 minutes or an injection. You’ll use it daily. You will participate for up to 15 months and have 17 visits at the study clinic.
The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time. To learn more about this study, click here.
Don't see a study that you qualify for?
Contact us to be added to interest list and you’ll be the first to know about our future studies! Send us a message by clicking the “contact us” button or call us at +1-843-851-7098.